Literature DB >> 326604

C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus.

O K Faber, C Binder.   

Abstract

Pancreatic beta-cell secretory activity was measured in 17 patients with insulin-dependent diabetes mellitus of less than 19 months' duration and in 10 nondiabetic subjects by means of the peripheral plasma C-peptide response to 1 mg. of glucagon I.V. The C-peptide response to a meal was also measured in the diabetic patients. Residual beta-cell function was present in all the diabetic patients as indicated by significant amounts of C-peptide in plasma. Significant increases in C-peptide were observed in 16 after glucagon stimulation and in 15 after the meal. Both absolute and relative increase in C-peptide were reduced in the diabetic patients. The increase in C-peptide was correlated to the fasting C-peptide concentration both after glucagon (r=0.86, p less than 0.001) and after the meal (r=0.66, p less than 0.01). The responses to the meal and to glucagon were correlated (r=0.77, p less than 0.005), indicating a high predictive value of the glucagon test as to how the beta-cells will respond during normal daily life.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 326604     DOI: 10.2337/diab.26.7.605

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  96 in total

1.  A simple clinical approach to discriminate between "true" and "pseudo" secondary failure to oral hypoglycaemic agents.

Authors:  L Scionti; P Misericordia; A Santucci; F Santeusanio; P Brunetti
Journal:  Acta Diabetol       Date:  1992       Impact factor: 4.280

2.  Correlation between fasting serum C-peptide and B cell insulin secretory capacity in diabetes mellitus.

Authors:  P Garcia-Webb; A Bonser; T A Welborn
Journal:  Diabetologia       Date:  1982-04       Impact factor: 10.122

3.  Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion.

Authors:  J C Pickup; G C Viberti; R W Bilous; H Keen; K G Alberti; P D Home; C Binder
Journal:  Diabetologia       Date:  1982-03       Impact factor: 10.122

4.  Metabolic parameters after changing from hydrochlorothiazide to verapamil treatment in hypertension.

Authors:  A Lehtonen; A Gordin
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Remissions in newly diagnosed type 1 (insulin-dependent) diabetes: influence of interferon as an adjunct to insulin therapy.

Authors:  V A Koivisto; A Aro; K Cantell; M Haataja; J Huttunen; S L Karonen; P Mustajoki; R Pelkonen; P Seppälä
Journal:  Diabetologia       Date:  1984-08       Impact factor: 10.122

6.  Glycaemic control in diabetic nephropathy.

Authors:  J J Bending; J C Pickup; G C Viberti; H Keen
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-21

7.  Evaluation of beta-cell function in diabetic Taiwanese children using a 6-min glucagon test.

Authors:  Yi-Ching Tung; Jing-Sheng Lee; Wen-Yu Tsai; Pei-Hung Hsiao
Journal:  Eur J Pediatr       Date:  2007-09-15       Impact factor: 3.183

8.  Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions.

Authors:  G B Bolli; E Tsalikian; M W Haymond; P E Cryer; J E Gerich
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

9.  Studies on overnight insulin requirements and metabolic clearance rate of insulin in normal and diabetic man: relevance to the pathogenesis of the dawn phenomenon.

Authors:  P De Feo; G Perriello; M M Ventura; F Calcinaro; G Basta; C Lolli; C Cruciani; A Dell'Olio; F Santeusanio; P Brunetti
Journal:  Diabetologia       Date:  1986-08       Impact factor: 10.122

10.  Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes.

Authors:  H J Gjessing; L E Matzen; O K Faber; A Frøland
Journal:  Diabetologia       Date:  1989-05       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.